Acquisition of VHH NGF programme & related assets

AI SummaryClose X

Animalcare Group plc (AIM: ANCR) acquired the VHH NGF programme and related assets from Orthros Medical for €0.7 million cash. This acquisition terminates a licensing agreement from March 2022 and grants Animalcare full ownership and control, eliminating future financial obligations, including development, regulatory, and commercial milestones and royalties. The VHH NGF programme researches antibodies for treating osteoarthritis pain in horses and dogs, complementing Animalcare's existing Daxocox product. This acquisition, coupled with a new partnership with 272Bio, allows Animalcare to independently develop and commercialize the technology across various species and indications, furthering its strategy of building a pipeline of innovative products. Early results from the lead equine asset show promise, and Animalcare plans to explore additional applications in larger animal health markets globally.

Disclaimer*

UK 100

Latest directors dealings